GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

"Competing interests PRO reports a consulting or advisory role with AbbVie, BMS, GlaxoSmithKline, Janssen, Pfizer, and Sanofi; is on the speakers’ bureau for BMS, GlaxoSmithKline, Janssen, and Sanofi; has received travel, accommodations, and expenses from Pfizer; and has received honoraria from AbbVie, Celgene, GlaxoSmithKline, H3 Biomedicine, Janssen, Pfizer, and Sanofi. NWCJvdD has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis; and reports a consulting or advisory role with AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Pfizer, Roche, Servier, and Takeda. KP is an employee of Janssen Oncology and report stock and other ownership interests in Johnson & Johnson/Janssen. IC is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. DV is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. KG is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. BH is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. JT is an employee of Johnson & Johnson and reports stock and other ownership in Johnson & Johnson; and has received research funding from Janssen Research & Development. TR is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson/Janssen. TM is an employee of Janssen Research & Development and reports stock and other ownership interests in Johnson & Johnson. CH is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and reports patents, royalties, and other intellectual property in Janssen Research & Development. CK is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and has received travel, accommodation, and expenses from Janssen Research & Development. PM has served in a consulting/advisory role and has received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Sanofi. NB has served in a consulting/advisory role for AbbVie, Amgen, Bristol Myers Squibb, Forus, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; has received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Forus, Janssen, Pfizer, and Sanofi; has received research funding from Pfizer; and has served as a member of an IRC and/or steering committee for AbbVie, GlaxoSmithKline, and Janssen. AC reports a consulting or advisory role for AbbVie, Antengene, BMS, Genentech, Genzyme, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics, OncoPeptides, Seagen, Secura Bio, Shattuck Bio, Shattuck Labs, and Takeda; and has received research funding from Amgen, Celgene, Janssen, Pharmacyclics, Seagen, and Takeda."

"Editorial and medical writing support was provided by Claire Line, PhD, and Craig Turner, MSc, of Eloquent Scientific Solutions, and was funded by Janssen Global Services, LLC."